Coop Norge selects Knowit and Mambu to modernise core banking platform
0
The new solution, powered by Mambu's cloud-native core banking platform and seamlessly integrated into Coop's infrastructure by Knowit, will modernise and streamline the management of millions of member accounts across Norway.
Coop is owned by 57 independent cooperatives with a combined membership base of over 2.3 million individuals. Each member is required by law to make a membership deposit when joining a cooperative, and may also make voluntary deposits which earn interest. These accounts are a cornerstone of Coop's member offering, and the new core banking system will ensure they are managed with security, transparency, and scalability.
'As a cooperative with millions of members and a long-term responsibility to safeguard their deposits, Coop needs a future-proof core banking solution. We are excited to work with Knowit and Mambu to deliver a modern platform that will support efficient operations, ensure regulatory readiness, and improve the overall member experience.' Jens Olav Bjørnson, Head of Digital channels, loyalty and marketing technology Coop Norge
Knowit will act as the lead system integrator, while Mambu provides the core banking engine through its SaaS platform. Together, they will deliver a modern, cloud-based core system tailored to Coop's cooperative model.
'We're proud to support Coop in delivering a robust and flexible core banking system. Our experience in modernising financial services across the Nordics, combined with Mambu's proven technology, ensures a smooth transition that will serve Coop's members for years to come.' Jan Georg Lehmann, Chief Commercial Officer Knowit Financial Solutions
'Legacy systems make it difficult to meet growing consumer and regulatory demands. With Mambu, Coop gains a cloud-native core banking platform that provides agility, compliance-readiness and scalability. Together with Knowit, we are excited to support Coop in transforming how they manage member deposits.' Jorno Levels Commercial Lead Nordics & Baltics Mambu
The project will run for four years, with an option to extend annually for up to eight years. Development of the new core banking platform is already underway.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
26 minutes ago
- Reuters
The race to launch first weight-loss pill
August 19 - Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's (LLY.N), opens new tab Zepbound and Novo Nordisk's ( opens new tab Wegovy. The GLP-1 drugs sold by both companies are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that might prove to be as effective as the injectables. Pills are easier to manufacture and could also avoid some of the supply issues that were initially seen with Novo and Lilly's drugs. Here are some companies developing oral obesity drugs in the hopes of making their mark in a lucrative market: Orforglipron, the company's once-daily oral non-peptide GLP-1 agonist, helped patients shed 12.4% of body weight over 72 weeks at the highest dose in a late-stage trial. Lilly plans to file for regulatory approval by the end of 2025 and is preparing for global submissions and manufacturing scale-up. Oral semaglutide, a pill version of the company's injectable GLP-1 active ingredient, demonstrated about 15% weight loss in a late-stage trial. The drug is currently under regulatory review, with a U.S. FDA decision expected in late 2025. Novo is also exploring next-generation oral combinations. Structure Therapeutics is developing GSBR-1290, a non-peptide oral GLP-1 agonist. Last year, the drug helped reduce weight by 6.2% on average at the end of 12 weeks in a mid-stage study. It is expected to report results from another mid-stage trial in the fourth quarter. The company, in partnership with Hansoh Pharma, is preparing to test HS-10535, an oral small-molecule GLP-1 agonist, in early-stage trials. The drug is currently being tested in lab studies. AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a promising weight-loss signal and a favorable safety profile, with mid stage trials planned under AstraZeneca's lead. Roche, following its acquisition of Carmot Therapeutics, is working on CT-966, an oral GLP-1 agonist. CT-966 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in an early-stage trial last year. The company is developing an oral formulation of VK2735, which targets both GLP-1 and GIP hormones that regulate the body's metabolism. In a mid-stage study of 280 overweight adults with at least one obesity-related comorbidity, the pill achieved up to 12.2% mean weight loss over 13 weeks, compared with placebo. Pfizer was developing danuglipron, initially as a twice-daily oral GLP-1 agonist, but scrapped development after data from a mid-stage trial showed poor tolerability. A once-daily extended-release version was later tested in about 1,400 patients but liver safety concerns remained, dampening the company's plans to enter the obesity drug market.
The Independent
27 minutes ago
- The Independent
Portugal prime minister insists ‘everything is ready' to return to F1 calendar
Portuguese prime minister Luis Montenegro has made it known his desire to see F1 return to the Algarve in 2027. The Algarve International Circuit last hosted an F1 grand prix in the Covid-impacted season of 2021, having returned to the calendar in 2020 in similar circumstances. However, amid new destinations such as Miami and Las Vegas being added to the schedule, Portugal fell off the list. Yet while the 2026 calendar has already been announced, Montengero is pushing for Portugal to return to the schedule in 2027. 'One of the circumstances that most contributes to promoting this region is major events," he said. 'We have secured the MotoGP, the world's premier motorcycling event, for 2025 and 2026. 'And I can tell you that we have everything ready to formalise the return of Formula 1 to the Algarve in 2027. 'These events require some financial effort on the part of the government, but they have a direct financial return and an indirect promotional return that are, quite frankly, well worth it.' However, it is a wide-ranging list of countries keen for a spot on the 24-race calendar. While Imola has not been included on next year's schedule, Madrid will be added to the list with a street circuit in the Spanish capital. Zandvoort, home to the Dutch Grand Prix, will drop off after next year's final event, while Barcelona's deal with F1 also comes to an end after next year. However, the likes of Thailand and South Korea are all keen on staging a race with a heap of bids from Africa too, with South Africa, Rwanda, Morocco and Nigeria all declaring an interest. F1 returns after the summer break next week with the Dutch Grand Prix (31 August).
The Independent
27 minutes ago
- The Independent
Clubs must wait until October for confirmation of 2026 Super League status
Super League clubs must wait until five days after this season's Grand Final to confirm their status in next season's potentially restructured top flight. The current top 12 clubs voted last month to expand the competition to 14 from 2026, subject to enough applicants meeting tight financial and sustainability criteria. The top 12 will still be determined by existing IMG grading scores, with the possible additional clubs picked by a seven-strong panel of experts. Clubs – including those who face the prospect of dropping out of the existing top 12 in the IMG table – must express their intention to apply by next Wednesday, with the composition of next season's Super League announced on October 16. Crisis-hit Salford, who are battling to complete their season after forfeiting last week's game against Wakefield, are expected to drop out of contention, effectively leaving three top-flight places up for grabs. The PA news agency understands that Bradford Bulls, who last played in Super League in 2014, are in pole position to replace Salford in the 12th spot, leaving Toulouse, York and London as front-runners for the remaining places. The panel, which will consider criteria additional to those already set out by IMG, specifically relating to financial status and sustainability going forward, will be chaired by RFL non-executive director Lord Caine. Caine said: 'I am honoured to have been asked to chair the panel to determine whether the Betfred Super League expands from 12 to 14 in 2026 and, if so, which clubs will take up the 13th and 14th positions in the competition. 'This panel consists of individuals with the considerable knowledge and expertise necessary to ensure that the process is both thorough and robust. 'All of our proceedings will be conducted on the basis of absolute fairness, rigorous impartiality between the applicants, total independence and, of necessity, complete confidentiality.' The seven-strong panel will also include two fellow non-executive RFL directors Abi Ekoku and Dermot Power, RFL chief executive Tony Sutton, interim head of legal Graeme Sarjeant, RL Commercial managing director Rhodri Jones and Super League (Europe) board member Peter Hutton. The composition of next season's Championship and League One competitions – which are expected to merge – is set to be confirmed later this week.
